Premium
Primary AL amyloid polyneuropathy successfully treated with high‐dose melphalan followed by autologous stem cell transplantation
Author(s) -
Katoh Nagaaki,
Matsuda Masayuki,
Yoshida Takuhiro,
Yazaki Masahide,
Morita Hiroshi,
Sakashita Kazuo,
Ikeda ShuIchi
Publication year - 2010
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21483
Subject(s) - melphalan , medicine , polyneuropathy , amyloid polyneuropathy , transplantation , amyloid (mycology) , stem cell , autologous stem cell transplantation , amyloidosis , peripheral neuropathy , al amyloidosis , pathology , immunoglobulin light chain , immunology , endocrinology , biology , disease , antibody , genetics , diabetes mellitus , age of onset
We report 2 patients with polyneuropathy associated with amyloid derived from light chains (AL) who were treated successfully with high‐dose melphalan followed by autologous peripheral blood stem cell transplantation (HDM/SCT). Neuropathic symptoms improved in conjunction with normalization of serum‐free light chains. In addition to amyloid deposits in tissues, an amyloidogenic light chain itself produced by abnormal plasma cells might be harmful to peripheral nerve function, and thus HDM/SCT seems to be a promising therapy for primary AL amyloid polyneuropathy. Muscle Nerve, 2010